Takeda Continues Recent Gene Therapy Partnering Spree With Poseida Pact

Takeda will use Poseida’s non-viral delivery and gene-editing capabilities for six liver- and hematopoietic stem cell-targeted gene therapies. The agreement follows recent gene therapy tie-ups with Selecta and Genevant.

Takeda Tokyo HQ
Takeda is partnering with biotechs on non-viral delivery of gene therapy

Takeda Pharmaceutical Co. Ltd. unveiled its third gene therapy collaboration in less than two months on 12 October, this time teaming with Poseida Therapeutics, Inc. on a research, development and licensing agreement for six gene therapy candidates, including one for hemophilia A.

The Japanese pharma is paying $45m up front for access to multiple Poseida technology platforms, with a plan to develop six gene therapy candidates in liver and hematopoietic stem cell-directed indications and potential to add two more programs. It comes a week after Takeda announced a tie-up with Selecta Biosciences, Inc

More from Gene Therapies

More from Advanced Therapies